logo-loader
viewImugene Ltd

Imugene has CheckVacc preclinical data published in the Journal of American College of Surgeons

The company’s preclinical results present an effective treatment against Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma (PDAC).

Imugene Ltd - Imugene confirms CheckVacc preclinical data published in the Journal of American College of Surgeons
Imugene is a clinical stage immuno-oncology company developing a range of new treatments to activate the immune system of cancer patients

Imugene Limited (ASX:IMU) has had preclinical data and results for its licensed oncolytic virotherapy CheckVacc published in the prestigious Journal of American College of Surgeons.

Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma (PDAC) is fatal and Imugene’s preclinical study presents an effective treatment against PDAC PC employing a novel oncolytic viral agent, CF33-hNIS-antiPDL1 (CheckVacc).

The title of the work is 'Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer' authored by Yanghee Woo MD, Zhifang Zhang PhD, Annie Yang MD, Shyambabu Chaurasiya PhD, Anthony Park BA, Jianming Lu BA, Sang-In Kim BA, Min Li BA, Susanne Warner MD, Daniel Von Hoff MD and chairman of the Imugene OV SAB Professor Yuman Fong MD.

While the paper details the results seen in pancreatic cancer, CheckVacc will initially be tested in patients suffering Triple-Negative Breast Cancer (TNBC), where equally important preclinical data has been collected.

Role of City of Hope

Imugene managing director and CEO Leslie Chong said the CF33-hNIS-antiPDL1 virus was effective in infecting and killing human PDACs and producing functional anti-PD-L1 antibody.

She said: “IP delivery of CF33-hNIS-antiPDL1 effectively reduces peritoneal tumour burden and improves survival after only one dose and is superior to IV delivery.

“The CF33 oncolytic virus (OV) was developed in the lab of Professor Yuman Fong, an internationally recognised surgeon and scientist at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in California.”

CF33 has been developed in two constructs – one version of the OV is armed with an immune checkpoint inhibitor inserted in the virus, which is known as CheckVacc and the other an unarmed construct, known as Vaxinia.

Journal of American College of Surgeons

The Journal of American College of Surgeons (JACS) is a monthly peer-reviewed journal with the goal of providing its readership with the highest quality rapid retrieval of information relevant to surgeons.

Contributions include original scientific articles, collective reviews, experimental investigations with clear clinical relevance, and a surgeon-at-work section (online only).

Quick facts: Imugene Ltd

Price: 0.035 AUD

ASX:IMU
Market: ASX
Market Cap: $154.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene receives $4.13 million R&D tax incentive boost for commercial and...

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019. Professor Fong is the inventor of the technology and spoke about...

on 12/11/19

2 min read